Our Archives section provides access to previously published issues, ensuring a comprehensive resource for researchers, practitioners, and educators.
Explore Past Issues
Volume 1
Issue 2 JULY– DECEMBER 2025
Volume 1 (Issue 2) JULY– DECEMBER 2025 Research Articles
Asian women: Safety and Efficacy of Sirolimus in the Management of Lymphangioleiomyomatosis: A Prospective Open-Label Study
Vol.1(2); Pages:1-8. Published on July-2025
Abstract
Lymphangioleiomyomatosis (LAM) is a progressive lung disease that is rarely observed in women of productive age, which is linked to the growth of abnormal smooth muscle cells in the lungs. The study was a prospective open-label study done to assess the efficacy and safety of sirolimus in 24 Asian women with proven sporadic LAM. Oral sirolimus (2 mg/day) was administered to the participants over 12 months and the clinical outcome was evaluated using pulmonary function tests (PFTs), serum VEGF-D concentrations and quality of life (QoL) parameters at baseline, 6 and 12 months. The findings demonstrated the drastic stabilization of FEV1 (mean decline = 30 mL/year or less) as well as the enhancement of QoL scores. Moreover, the concentration of VEGFD decline meanly by 28-percent (p < 0.05). Mild stomatitis and hyperlipidemia were the common adverse events that were well-managed. These results help to maintain sirolimus as a possible long-term treatment of LAM and underline the face value of regional data to direct the utilization of orphan drugs in Asian patients.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Pegylated Interferon-Lambda in Chronic Hepatitis D Virus Infection: A Phase II Randomized Trial: Clinical Evaluation
Vol.1(2); Pages:9-18. Published on July-2025
Abstract
HDV is an uncommon, but a severe condition of the liver that has few treatment options. The safety and efficacy of pegylated interferon-lambda (PEG-IFN-lambda) were compared to that of pegylated interferon-alpha (PEGIFN-alpha) in patients (n=64) with HDV in this Phase II randomized controlled trial. Participants were injected subcutaneously to receive injections on a weekly basis over 48 weeks. Primary outcomes were overall virological response and ALT normalization whereas tolerability was the targeted secondary outcome. Statistically significant results included a 42 percent virological suppression percentage in the PEG-IFN-A arm compared to 21 percent in PEG-IFN-Lambda) with a significantly reduced flu-like symptoms and hematologic toxicity in the PEG-IFN-Lambda arm. PEG-IFN-lambda patients experienced the normalization of the ALT in 39 percent of patients. This result enhances the use of PEG-IFN-lambda as a potential treatment strategy since long-term validation is critical as further Phase III studies are required.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Compassionate-Use Nusinersen in Adult Spinal Muscular Atrophy Type II: Real-Life Multicentre Data
Vol.1(2); Pages:19-29. Published on July-2025
Abstract
Spinal muscular atrophy (SMA) Type II is a relatively uncommon neuromuscular disorder and it lacks much adult experience in treatment, with most of the clinical trials confined to the pediatric population. This retrospective multi-centered study evaluated the usage of nusinersen in 58 adult patients with SMA-II across the centers in Asia and Europe under compassionate use. Clinical parameters were motor (Hammersmith Functional Motor Scale-Expanded), respiratory, and safety outcome after 24 months. Sixty-seven percent of patients showed stabilization or slight improvement in motor functions with 12 percent of patients developing improvements in ambulation support. There was improved respiratory functioning when compared to natural history information. The safety can be considered consistent between the prior pediatric studies, where the adverse events associated with the lumbar puncture were the most frequent. Notably, patients indicated significant changes in improvements in community-based independence and daily living. This report offers the biggest real-life experience with the use of nusinersen in adult SMA-II and confirms its therapeutic relevance in all ages.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Oral histone deacetylase inhibitor in the treatment of refractory peripheral T-cell lymphoma Phase II
Vol.1(2); Pages:30-38. Published on August-2025
Abstract
Peripheral T-cell lymphoma (PTCL) is an uncommon and aggressive non-Hodgkin lymphoma subtype with few treatment options on progression after standard chemotherapy. We conducted an open-label Phase II trial of an oral histone deacetylase inhibitor (HDACi) in 42 patients with relapsed or refractory PTCL. Patients were dosed at 200 mg once daily in 28-day cycles to disease progression or intolerable toxicity. There was a 36 percent response rate (14 percent complete and 22 percent partial). Progression-free survival median was 5.2 months. Side effects associated with treatment consisted of thrombocytopenia and neutropenia as well as gastrointestinal manifestations that were tolerable with the assistance of dose reduction and supportive management. These results encourage the clinical utility of HDAC inhibition in heavily pretreated PTCL patients and justify future randomized studies to evaluate combination regimens.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Systematic Review and Meta-Analysis of New Treatments to Pulmonary Arterial Hypertension with Connective Tissue Disease
Vol.1(2); Pages:39-47. Published on August-2025
Abstract
CTD-PAH is a rare, but severe disease characterized by the progressive vascular remodeling with poor prognosis. The procedure of this systematic review and meta-analysis involved the collection of data provided by 15 clinical trials and 9 observational studies with 2,312 patients. ERAs and PDE5is lowered pulmonary vascular resistance by 32 percent less than placebo or increased 6-minute walk activity distance by 48 meters, respectively. Prostacyclin analogues provided a significant benefit on 3-year survival (HR 0.67; 95% CI 0.51 0.88). Combination therapies were found to be more effective in terms of more functional and hemodynamic outcomes. Peripheral edema, headache, and flushing were the common adverse events. These results suggest enhanced implications of individualized multimodal treatment strategies in the CTD-PAH paradigm, which has implications of better long-term outcomes in this high-risk cohort.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Issue 1 JANUARY- JUNE 2025
- Volume 1(Issue 1) JANUARY- JUNE 2025
Volume 1(Issue 1) JANUARY- JUNE 2025 Research Articles
Redesigning Curriculum through a National Framework to Strengthen Student Clinical Proficiency
Vol.1(1); Pages:1-9. Published on June-2025
Abstract
Institutions are adjusting their curriculum to meet both the changing needs of healthcare and to create graduates who can practice skills needed at the national level. The paper discusses how a national framework is being implemented to help teachers develop and implement new health education lessons that deepen students’ clinical skills. The study stresses a focus on the learner and final goals and describes how to include clinical reasoning, working with other professionals, patient-centered care and evidence-based practice into programs. The new curriculum is designed to match national standards and what stakeholders such as regulatory bodies, teachers, partners and students, expect which guarantees that what is taught remains relevant and can be used directly in clinical practice. The paper outlines that ongoing work on curriculum mapping, involving different groups, supporting instructors and measuring skill development unite the educational path from school to healthcare practice. Based on these findings, the framework-based redesign is connected to stronger clinical experience, greater faith in treating patients and improved ability to work alone, making the healthcare workforce stronger. The findings demonstrate that frameworks set by each nation are important for developing competency-based, proactive and responsive education systems.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Essential Knowledge for Upcoming Healthcare Professionals: WHO’s Pharmacovigilance Core Curriculum with a Focus on Clinical Practice
Vol.1(1); Pages:10-16. Published on June-2025
Abstract
By performing pharmacovigilance, we ensure that both patients and clinical care are protected from harms or serious side effects due to medicine. The WHO has collected a main curriculum to educate medical professionals on the basics and skills needed for pharmacovigilance. By including pharmacovigilance practices, this curriculum ensures that clinical practice leads to safer medication, wise drug habits and better patient outcomes. With the help of this curriculum, healthcare professionals learn how to contribute productively to national and global efforts in drug safety. In this article, we point out what the WHO emphasizes in its curriculum and explain its role in preparing future clinicians for work in pharmacovigilance.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Designing External Approaches for Assessing the Effectiveness of Community Pharmacy Services
Vol.1(1); Pages:17-24. Published on June-2025
Abstract
Finding out how high the quality of pharmacy services is ensures better health care can be given in the community. This research is focused on designing and proving the reliability of tests for measuring the effectiveness of services by community pharmacists. The suggested models address the gap of previous tools by using data from patients, guidelines from regulators and reviews from external experts. Patient counseling standards, help with medication adherence and making care accessible to patients are highlighted in the research. It appears that using independent evaluation methods designed for pharmacy activities can greatly improve transparency, accountability and ongoing improvement in the practice.
View Full PDF
Please LOGIN to View Full PDF or Read more.
A Descriptive Case Study of Community Pharmacists’ Identification of Medication-Related Issues in Two Australian Populations
Vol.1(1); Pages:25-32. Published on June-2025
Abstract
Primary care settings are especially at risk for medication-related problems (MRPs) which can threaten both patient safety and results in healthcare. This investigation analyzes the MRPs experienced by patients as recognized by community pharmacists from both an urban and a rural region of Australia. Thanks to direct pharmacist reports, records of interventions and in-person assessments, we gain valuable insight into both the clinical importance and character of the problems studied. Important MRPs found were drug–drug interactions, having multiple treatments for the same medical reason, giving inaccurate dosages, when patients do not take the medicine as directed and when their medicines are not regularly monitored. Urban patients were more prone to problems because of multiple medicines, while the rural cohort struggled with access to healthcare and regular follow-up. The discovery reveals that community pharmacists, serving as the main healthcare providers in communities, can identify and resolve MRPs, so patients stay safer and healthier. This research points out that it is important for pharmacists to be a regular part of multidisciplinary healthcare groups and suggests greater help for pharmacist-directed treatments in both urban areas and rural areas.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Does Getting Prescription Substances Affect A Person’s Ability to Quit Smoking as a Result of Being Insured?
Vol.1(1); Pages:33-39. Published on June-2025
Abstract
The impact of having health insurance for smoking cessation medicines on a person’s ability to quit smoking is examined in this study. To see if policies affect quit rates, the research examines how many patients are using nicotine replacement therapies, varenicline and bupropion. It goes on to study differences in demographics, how co-payments work with insurance policies and what support services are connected to coverage. The results indicate that full insurance cover, along with appropriate interventions and lower out-of-pocket costs, improves the chances of stopping smoking.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
